StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Amgen (AMGN) & Allergan (AGN) Report U.S. FDA Submission of Biosimilar Biologics License Application For ABP 980
July 31, 2017 9:03 AM
Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced the submission of a Biologics License Application (BLA) to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Next Articles
Amgen (AMGN) Reports Submission of Supplemental Biologics License Application For Prolia (denosumab)
July 31, 2017 9:12 AM
Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration
July 31, 2017 9:00 AM
Amgen (AMGN) Declares $1.15 Quarterly Dividend; 2.6% Yield
July 28, 2017 4:01 PM
AbbVie to remain cautious on drug pricing, shares fall
July 28, 2017 7:54 AM
Amgen (AMGN) Says FDA Grants Priority Review For its sBLA For Repatha to Include Data On Reducing Risk Of Cardiovascular Events
July 27, 2017 5:51 PM
Amgen (AMGN) PT Raised to $195 at Argus on 2Q Report; 'Contributors to Top-Line Growth: Kyprolis, Prolia & Sensipar'
July 27, 2017 10:11 AM